Weihao Xu
Founder & Chief Executive Officer Kali Therapeutics
Seminars
Thursday 25th June 2026
Breaking the Potency-Toxicity Link: Maximizing Therapeutic Index via Kali’s Masked Multispecific Portfolio
3:30 pm
- The Decoupling Strategy: A high-level overview of how Kali’s masking platform effectively breaks the linear correlation between T-cell potency and systemic cytokine release. We will demonstrate how conditional activation allows for Kali’s TCEs that maximize target-cell killing while maintaining a superior systemic safety profile
- KT501: Driving Deep B-Cell Depletion: An examination of the mechanistic advantage of targeting CD19 and BCMA simultaneously. This section focuses on the potency of the trispecific architecture to achieve more comprehensive B-cell and plasma cell depletion than traditional bispecifics, supported by the protective "safety window" provided by our masking technology
- Optimizing the Next Generation (KT502 & KT209): A look at the strategic engineering behind our upcoming pipeline. We will discuss how KT502 (CD19xCD3) and KT209 (CD19xCD20xCD3) are designed to overcome antigen escape and resistance in B-cell malignancies by combining high-potency multispecific engagement with masked activation
